Considine announced the A-share sign-off rate, the vaccine take off under the "war" to the end!?

Guide: Vaccine enterprises rise, unrealized revenue "Consino" can accelerate the "overtaking"! The 2020 Fortune China 500 list released the day before, in the pharmaceutical industry shortlist of enterprises, revealed the results, but also revealed the industry under the quiet changes.
years ago a party of the harpharma group, Tongren Tang, step pharmaceutical and other enterprises in recent years have disappeared from the list disappeared, and Hengrui, stone medicine, Fosun and other newcomers have entered the scene, "Jiangshan generation of talented people out, each lead the wind for hundreds of years" to show the most vivid. the rise of
innovative drugs is the time has given some of the original accumulation of good, but has excellent vision of Chinese pharmaceutical companies to catch up with or even overtake the opportunity.
and this one of the Fosun Pharma, Hengrui Pharmaceuticals, Collon Pharmaceuticals and a number of advantages of the enterprise strong Hengqiang.
Baiji Shenzhou, Cinda Bio, Junshi Pharmaceuticals, Pharmaceuticals and Other innovative pharmaceutical companies are also rising.
"vaccine" was undoubtedly elected as the "keyword" of the times and to talk about the hottest industry in recent times, vaccines can definitely stand up.
in the industry, the world's top ten vaccine varieties are basically all from GSK, Sanofi, Mercado, Pfizer four vaccine giants, and most of the varieties are ancient.
and China as a large country of vaccine demand, the total scale of the market growth is rapid, the average annual compound growth rate of nearly 10%, the global strong enterprises salivating, domestic enterprises want to get a piece of the pie, strength and opportunity has become the key.
and through this year's epidemic catalyzed, the domestic vaccine industry just ushered in a new round of development.
Kantai biology, Zhifei biology, Changchun high-tech, Kangsino biology and so on layout "new crown vaccine", have the opportunity to achieve the idea of enterprise take-off.
the outbreak is not fully under control, is it good for "Consino"? On July 27th, a small outbreak broke out again, with new cases in Xinjiang and Dalian hitting a new high in a single day.
the situation of epidemic prevention at home and abroad is still not optimistic, in the absence of effective drugs for the virus, in order to implement the vaccine weed-cutting root, vaccine research and development and supporting industrial chain is still a hot market.
and following the July 31 kangsino opened the purchase, this netizen called "the first share of the new crown vaccine" enterprise also recently announced the a-share online issuance of the final signature data, the number of effective purchase of 4.795 million households, the number of effective purchase shares of 20,752 million shares, the initial online issuance of the signing rate of 0.02198832%. as a company dedicated to the development, production and sale of innovative vaccines,
rapidly promotes the development of a series of innovative domestic vaccines, including meningitis prevention, Ebola virus disease, white pneumonia, pneumonia, tuberculosis, new coronavirus (COVID-19), shingles and other adaptations of clinically high-volume vaccines.
developed 15 research vaccines in 12 disease areas, in addition to the three near-commercialized vaccine products for meningococcal infection and Ebola virus disease prevention, six are in clinical trials or applications for clinical trials, and six preclinical vaccines are in development, including one in research.
company and the Institute of Biological Engineering of the Institute of Military Medical Research of the Military Academy of Sciences jointly developed and recombined the new coronavirus vaccine (adenovirus vector), the clinical trial swelled, the progress of the first, began Phase II clinical trial in April, in June to obtain Phase II clinical trial research data, phase III clinical trial program has not yet been finalized.
unrealized earnings, competitors continue to increase, Consino said in a prospectus, the company's vaccine products have not yet achieved commercial sales, and will continue to invest in research and development, production base construction.
the company has not yet made a profit and will continue to lose money for some time to come.
well-known product Ebola virus vaccine "Ad5-EBOV" only supply of emergency use and future national reserve arrangements, only under the guidance of the relevant national health management departments, the company will be based on the country's special needs arrangements for production, will not become the company's main source of future revenue.
this year, "Consino" to market the "new crown vaccine", not only the United States biotech company Moderna, Germany's BioNTech and other companies have entered the clinical trial stage of the vaccine.
domestic competitors can not be ignored, Wuhan Institute of Biological Products and Beijing Kexing Zhongwei Biotechnology Co., Ltd. inactivated vaccine, The National Pharmaceutical Group of China Biological Wuhan Biological Products Research Institute developed a new crown pneumonia virus inactivated vaccine, are closely followed.
can be said to be a little lax, all efforts will be lost.
summary overall, the domestic vaccine industry space is large, the growth of the domestic vaccine industry can be rapidly comparable to innovative drugs, the future will be a large extent to obtain qualitative improvement, leading enterprises to go abroad.
and in the case of "Consino Biology", the vaccine industry product line layout is wide, research and development team domestic first-class, in the short term can rely on the "new crown vaccine" to achieve beach landing, enhance the industry's influence, steady and stable to achieve self-breakthrough.
and on the long line, if we can step up the commercialization of vaccines, it will greatly encourage market confidence, faster self-worth.
finally, from the near-end time capital market performance, as the new crown vaccine clinical timeline advances, the medium-term vaccine speculation space may be further enhanced.
at the same time, but also need to always beware of withdrawal risk, after all, "new crown vaccine" has not been successfully developed before, who do not know who the first will be!